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FOREWORD 
Foreword 
The Committee on Energy, Research and Technology of the European Parliament organized a 
Hearing on Biotechnology on 20/21 November 1985 in Brussels. This hearing stressed the 
need for more cooperation in European research and development in order to strengthen the 
position of Europe vis-a-vis Japan and the United States and underlined the need for interna-
tional regulations in biotechnology. Furthermore, the hearing aimed at highlighting complex 
problems relating to the possible consequences of biotechnology for agricultural policy in 
Europe and problems relating to the impact of biotechnology in the Third World. 
The main objective, however, of this hearing was to collect further facts and information for 
the Committee's own-initiative report by Mrs. Phili VIEHOFF, MEP. Her report is to be debated 
in the Parliament during the first half of 1986. Mrs. VIEHOFF has already been the Commit-
tee's rapporteur (Doc. 2-1144/84 and Resolution of 14 December 1984, OJ C 12/85, pp. 
144-146) on the current multiannual research action programme for the EEC in the field of 
biotechnology (1985 to 1989) (Council Regulation 85/195/EEC of 12 March 1985, OJ L 83/85, 
pp. 1-7). 
The Directorate General for Research and Documentation has been asked to summarize this 
hearing. This document contains a short synopsis of statements made by experts on the 
different topics and a summary of the subsequent discussions . 
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Introduction 
Mrs Phili VIEHOFF, Member of the European Parliament: 
Biotechnology and the Role of the European Parliament 
The tasks and the role of the European Parliament are 
limited and therefore cannot be compared with the role 
of Congress in the United States or with the role of 
national parliaments. The European Parliament does 
however have three important tasks: 
- to advise the council and to control and advise the 
European Commission; 
- to initiate studies and investigations; 
- to influence and reflect public opinion and to raise 
public awareness. 
These tasks can become powerful tools when used to 
instigate discussions on high technology in general and 
biotechnology in particular. Already in October 1980 the 
European Parliament discussed the potential, the use-
fulness, the limitations and the possible risks of biotech-
nology. A comprehensive report made by Mr Gerhard 
Schmidt (Working Document 1-521 /80) formed the 
basis for this discussion which led to some changes in 
and modifications of the Commission proposal for the 
Biomolecular Engineering Programme. This Pro-
gramme has proved successful and has laid the founda-
tions for the multiannual European Biotechnology Ac-
tion Programme, which started recently. 
Before this Action Programme was accepted in Decem-
ber 1984, a second broad discussion took place in the 
Parliament. This discussion had a different character 
from the discussion in 1980. The rapid advancement in 
scientific progress and the growing interest of industry 
in applying biotechnology for the creation of new pro-
ducts and processes, as well as the steep rise in finan-
cial efforts made by the United States in this field and 
the Japanese guided joint approach, formed the back-
ground to the discussion this time. 
Althougt1 it was agreed unanimously that a European 
Biotechnology Action Programme was necessary if 
Europe did not want to fall back to an uncompetitive 
position vis-a-vis the United States, Japan and even 
some newly industrialised countries, an attempt was 
rnade to take the discussion beyond this well-known 
statement. 
Besides stressing the need both for international regu-
lation of biotechnology and the importance of advanced 
European support industries for large-scale develop-
ment of biotechnology, as well as the need for a policy 
that could prevent a brain drain from Europe to the 
United States, there were other and perhaps more com-
plex problems in the medium and long term that should 
get more attention too. 
There 1s one other new initiative I would like to mention. 
That is the proposal for the establishment of a Euro-
pean Parliament Office for Scientific and Technologi-
cal Option Assessment (OSTOA). This office will 
assess science and technology policy and will formulate 
alternatives for the development and application of 
technologies and organisational structures. As far as 
biotechnology is concerned, I think this European 
OS TOA can function as an important resource base for 
Members of Parliament and help to prepare further dis-
cussions and to raise public awareness on a broader 
scale. Let me now move on to four issues that need 
more attention in the years to come. 
First, the question of access to and distribution of 
biotechnology. Biotechnology offers an enormous po-
tential for many different industries and countries, but it 
is obvious that the distribution of biotechnology is very 
unequal. This situation is aggravated by the fact that 
biotechnology research is often carried out in the pri-
vate sector. One of the most problematic implications of 
this is the restriction on broad access to new agricultu-
ral and pharmaceutical biotechnology advances. This 
situation could easily lead to tensions and even political 
conflicts between states. An illustration of this is the 
limitation on the potential of biotechnology for Third 
World countries because of their inability to gain access 
to the technology. But on a more subtle level the same 
conflicts could occur between industrialised countries, 
particularly if we think about the possible effects of 
export control policy on high technology. Until now it 
seems that many European companies have not been 
aware of or have not wished to acknowledge the threat 
of being cut off from American high technology or from 
parts essential to their products. However, we should 
not underestimate the extraterritorial jurisdiction of the 
United States. 
Secondly, the issue of regulation and risks. Genetic 
manipulation of micro-organisms and plants will un-
doubtedly result in enormous benefits for human health, 
crop production, veterinary medicine, and pollution con-
trol. But what about the risks? 
As biotechnology is exploitec by industry, commercial 
objectives will lead to incre 1singly varied uses and 
increasingly varied hazards. Entrepreneurs may be-
come less cautious when the 'I see high profits on the 
horizon. This can become p,trticularly relevant in the 
case of large-scale industrial r 1rocesses and in cases of 
the deliberate release of ma11ipulated organisms into 
the environment. Field tests ,1ave already been made 
involving the deliberate rele 1se of genetically engi-
neered organisms into the environment. What is at 
issue is whether a foreign c,rganism will disrupt the 
ecosystem into which it is introduced. However, scien-
tists have insufficient information to predict the ecolog-
ical consequences of genetic t·ngineering. Although the 
risks from genetic engineerinr1 so far appear to be low, 
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the consequences of an accident could be enormous. 
More basic research and testing in microcosm are 
necessary to reduce the uncertainties. Factors such as 
release, survival, multiplication, dissemination, and 
~ransfer should be included in new risk assessment 
methods. It is a pity that the international efforts at 
OECD level have failed to establish harmonious regula-
tory programmes because the American delegation 
could not accept the text of the proposed international 
guidelines. I am afraid that the American delegation's 
attitude has a strong political and economic back-
ground. namely to prevent a too strong regulation for 
the American firrns at home and abroad. In the US there 
is intensive lobbying from industry to reduce regulation 
and to regard biotechnology products as normal chem-
ical products. This would prevent new regulations and 
would save time. It would facilitate the marketing of 
American biotechnology products and would give these 
companies an advantageous position in the face of 
fierce international competition. We should prevent the 
realisation of such a policy in Europe. Here in Europe we 
should show a more responsibile attitude. to reduce the 
possible risks and avoid the misuse of national regula-
tion policies. We should establish European regulation 
guidelines as soon as possible. 
Thirdly, the restructuring of agriculture. Although until 
now biotechnology applications have been concen-
trated upon pharmaceuticals and diagnostics, the mar-
ket for agro-food products is estimated to be much 
larger. Biotechnology and the increasing use of informa-
tion technologies will change the existing structure of 
agriculture and lood-processing. ThP. traditional essen-
tial for growing things, still vitally important, are land, 
water and farmers. New ingredients include seeds. 
genes and chemical molecules. The importance of 
seeds is reflected in the buying-up of small seed com-
panies by large pharmaceutical and (petro) chemical 
corporations. In addition, the seeds themselves have 
changed. Specific genes have been transferred from 
one species to another to increase crop yield, and to 
make plants resistant to diseases, insects and even 
drought. 
Although these achievements are very promising, a 
drawback is that these advances in plant genetics are 
supported by the continued increased use of chemicals 
on the land, such as pesticides, herbicides and fertilis-
ers. A serious danger is that producers will use even 
greater amounts of herbicides in the long run, because 
their seeds will be resistant to these increased 
amounts. This development is dangerous for public 
health and should be monitored much more closely. 
Also the growing dependency of farmers on the concen-
trated seed industry and their 'package-policy' should 
be given more attention. 
It is unlikely that industry will stimulate research and 
development on seeds that no longer require agro-
inputs, although theoretically this is possible. However, 
the profit-orientated thinking of industry and the high 
stakes in the existing agro-input market will prevent 
this. This illustrates the distinction between the full 
potential of biotechnology and the actual direction of 
private research carried out by companies. 
If we look at the consequences of biotechnology and 
information technology for the farmers, then it becomes 
clear that the farmer of the future will spend less time on 
a tractor and more time at his computer, programming 
minute details about his crops, plugging into data 
gathered by satellites, and keeping up on the latest in 
genetic manipulation. This highly sophisticated busi-
ness will give employment to only a few farmers. 
According to recent American research at least half of 
America's food will be produced by only 1% of the 
farms. The employment problem created by this could 
be serious in Europe too, particularly in the new EC 
countries like Portugal, Spain and Greece. 
That is not all. Genetically manipulated seeds can 
change the whole regional and international division of 
labour in agriculture. Crops that used to be grown in the 
South can be shifted to the North when tor example the 
resistance of plants to colder climates is increased. 
The consequences for agricultural and related trade 
between industrialised countries and between Third 
World countries and industrialised countries could be 
far-reaching. Although it all sounds still very futuristic, 
and although much research has still to be done before 
this situation is reached, development towards this sit-
uation seems unavoidable. In the European Parliament 
all Committees involved in agriculture, technology, envi-
ronment and industry have to consider these possibili-
ties. 
There is increasing recognition of the fact that the exist-
ing agricultural policy has become untenable. Nearly 
70% of the budget is spent on agriculture and this limits 
the possibilities for many other useful initiatives and 
programmes. Biotechnology will lead to a restructuring 
of agricultural policy on a much broader scale and per-
haps much taster than has been acknowledged until 
now. This restructuring in the sense of changing and 
cutting subsidies, changing price policy for agricultural 
products used for industrial production, and the retrain-
ing of farmers is essential if we want to make the most 
of this enormous transformation and if we want also to 
direct development in a socially and economically 
acceptable way. This issue will become very important 
in the next decade. The European Parliament started 
the discussion last year and will continue it because this 
is a complex problem that should be resolved on an 
international scale. The European Parliament is an 
excellent platform for the discussion of the different 
options at an early stage. 
Fourth, and lastly, I would draw attention to the socially 
useful products. What do I mean by this? If we look at 
the direction of commercial research and at the new 
biotechnology products, commercial incentives clearly 
exist for high value added products and not for uses of 
biotechnology which have little commercial value, but 
high social value, like malaria vaccine. However, 150 
million people catch malaria every year and biotechno-
logy could lead to a new cheap vaccine. The same can 
be said for other common virus diseases. But industry is 
not interested in poor people's needs. Industry is not 
interested either in fighting rare diseases where there is 
no commercial interest. Investments in the so-called 
'orphan drugs' are high and profits low, because the 
market is very limited. However, the potential of bio-
technology is very promising in this field and should be 
developed further. This is also true for a terrible disease 
like AIDS. The European Parliament has asked for more 
biotechnology-related research to speed up the devel-
opment of diagnostics and medicines. 
If we look again at the potential of biotechnology for 
food production, it would be logical to stimulate the 
development of tissue culture or other biotechnology-
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based techniques in areas near the starving populations 
of the Third World, instead of shipping our overcapacity 
to these countries. However, the protection of farmers 
in industrialised countries prevents this. Also the fact 
that we know very little about rice, the world's largest 
food crop. limits the horizons of ~ompanies. 
In the field of toxic waste treatment biotechnology 
seems to offer attractive possibilities. It might be possi-
ble to create special organisms that could digest toxic 
wastes. And enzymes in fermentation processes might 
catalyze a much more complete and rapid degradation 
of particular wastes. 
Also in the field of local, small-scale energy production 
biotechnology can play an essential role, particularly in 
developing countries. 
Biotechnology - if regulated properly - can offer 
many promising solutions for food, health, energy and 
waste problems in North and South. However, many of 
these developments offering important public benefits 
will be neglected by profit-seeking industry. Therefore, 
it is necessary to be selective in setting up biotechno-
logical programmes. Industry knows where profits are 
to be found and will not invest if they are not sure of their 
returns. Now that the European Biotechnology Action 
Programme has begun, in parallel with many national 
government biotechnology programmes, we should re-
consider our starting points. An important task for the 
European Parliament is to monitor useful applications of 
biotechnology that for commercial reasons will not be 
picked up by industry. The path the European Parlia-
ment should follow is that of public benefit. More funds 
should become available for research and development 
programmes that make qualitative contributions to the 
well-being of people, without concentrating on short-
term profits. Close examination of the results of the 
European Biotechnology Action Programme and sug-
gestions for new directions wrll be an important task of 
the European Parliament, together with the proposed 
European Parliament Office for Scientific and Techno-
logical Option Assessment. 
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Part I: 
General overview on biotechnology 
1. Prof. Dr. THOMAS (Universite de Technologie 
de Compiegne): 
The state of European research in biotechno-
logy 
1. The European biotechnology situation is unfavour-
able when compared with the USA and Japan. Howev-
er, Japan is disadvantaged by not having direct access 
to agricultural raw materials. 
2. No European country dominates the biotechnolo-
gy market. West Germany and France possess special-
ised knowledge of microbiology. The UK leads in the 
field of protein-design. Belgium and Italy are leaders in 
plant conservation and gene technology. 
The technology exists in Europe, but improved coordi-
nation of research etc. is vital. 
3. Until now biotechnology applications in Europe 
have been concentrated in the pharmaceutical and diag-
nostic fields. This technology should be extended to 
European agriculture for the resolution of common 
problems. 
4. Research collaboration must be encouraged. Little 
international research exchange existed in Europe in 
the past. However, there has been improvement since 
the introduction of the Biomolecular Engineering Pro-
gramme (SEP) (1) which has a fund of 15 Mio ECU. 
5. Europe-wide training is necessary, using an inter-
disciplinary scientific approach. 
6. Collaboration between European industry should 
be encouraged. Legal barriers have caused delays. 
Therefore. a coordinated legal system is required. 
7. Improved relations between research centres and 
industry is needed, so that biotechnology applications 
are deployed to maximum effect. 
8. These are positive signs: the implementation of 
these measures could enable Europe to challenge the 
USA and Japan in the field of biotechnology researct1. 
9. During the following discussion Dr. THOMAS was 
asked about training, finance and the extent of the pro-
posed collaboration. 
10. He believed that training should reflect the inter-
disciplinary nature of biotechnology, involving a team-
work approach by scientists, as 'one person alone can-
not be a biotechnician ·. It is also desirable that there 
should be an effective interchange between academic 
and industrial experience, allowing university-based 
scientists an opportunity to work in an industrial envi-
ronment. 
(') Research and training programme for thP EEC i11 the field of bio-
molecular engineering (indirect action April 1982 to March 1986), 
Council Decision (81/1032/EEC) of 7 December 1981. OJ L 375/81, 
pp. 1-4. 
11 . Countries which are at a disadvantage where 
biotechnology is concerned have a chance to work with 
countries which are more advanced, thus allowing for 
regional development. 
Regarding plant molecular biology a small country like 
Belgium with intensive land use has certain advantages 
over a large agricultural country like France. Collabora-
tion therefore is useful and already much compatibility 
exists in Europe. 
12. Low investment restricts biotechnology develop-
ment in Europe. On the other hand, in the USA it 
depends on private risk-capital which is more freely 
available and therefore government intervention is not 
required. Because in Europe investment of ttiis type is 
not forthcoming, it is necessary to find alternative 
sources of capital. Dr. THOMAS believes that banks 
may be attracted to biotechnology as an investment 
option. The state function should be as an investment 
regulator. 
EUREKA's role as a possiblP source was questioned. 
Dr. THOMAS stated that it$ function was merely to 
provide initial investment stimulus as a framework for 
the commercialisation of research. Important action 
programmes already exist in parts of Europe, such as 
West Germany. Overall, BAP (1) is the most important 
programme on a general European level, having 
financed 170 projects. But giv,m that 800 requests have 
been made, many of which '..1ere perfectly viable, it is 
obvious that much more rem. !ins to be done. 
13. International collabora '· ion is hindered severely 
because individual companiE--s are eager to maintain 
development and production confidentiality. Therefore 
Europe's patent system must be coordinated. 
14. The European price structure is another major 
problem because the agricult1 Jral raw materials needed 
for biotechnology are over-pr ;ced. A price reduction in 
starch, for example would ha1 e no effect because there 
are more than 350 products n quired for starch-prod,uc-
tion, of which only one-third . ire sold on the food mar-
ket. 
2. Dr. POTTER (Science & Engineering Research 
Council (SERC), UK): 
Project Management in Europe 
How to define project management in biotechnolo-
gy? 
15. Broadly speaking proJ~ct management in t;>io-
technology is similar to pro:ect management in any 
branch of science. Where it differs from most o\her 
(1) Multir1nnual research action prog· .]mme for the EEC in the field of 
biotechnology (1985 to 1989), Co ncil Decision (85/195/EEC) of 12 
March 1985: OJ L 83/85. pp. 1-7 
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fields is in the way biotechnology affects project initia-
tion and management. In particular biotechnology is 
highly multidisciplinary and the projects typically involve 
two or more disciplines. As many industrial sectors and 
government departments or public bodies have inter-
ests in biotechnology, there is a need for a very high 
degree of coordination and cooperation in biotechnolo-
gy projects. 
What is the optimal size in terms of personnel for a 
biotechnology project? 
16. The minimum size for an effective multidisciplina-
ry project is 3 post-doctoral fellows plus technician sup-
port. The maximum size is limited by the ability to man-
age a large group of people, sometimes in different 
laboratories. 
17. The availability of suitable qualified people varies 
from country to country. Within the UK data exist for 
supply and demand and also for the loss of biotechno-
logists to other countries i.e. the 'Brain Drain'. The loss 
from the UK has occurred mostly to the USA and, to a 
lesser extent, Switzerland. 
What is the most favourable environment for project 
management in biotechnology - industrial, academic, 
green-field or other? 
18. In general, project management based outside of 
the sector(s) where the work will be undertaken is best. 
Within the UK the Biotechnology Directorate manages 
programmes involving both academia and industry. 
This central position involving a wide range of organis-
ations without being part of them is the most effective 
environment for project management. International pro-
jects linking various countries within the Community are 
possible and desirable. The decisive first step would be 
to build confidence between the participating groups in 
the different countries. Where it is not clear that cooper-
ation will benefit all the participants, projects will not 
succeed. 
What are the difficulties in bringing biotechnology 
from the laboratory to commercial application? 
19. Such a transition is easiest when the idea origi-
nates within the firm that subsequently exploits the 
results. The most effective transfer of technology from 
academia to industry is brought about by the movement 
of people from one to the other, at least for a short 
period of time if not permanently. 
20. Most of the earliest biotechnology products to 
come onto the market will be in the health-care field. 
Many of these products will require acceptance by reg-
ulatory bodies and obtaining such acceptance is expen-
sive and time-consuming. Some companies may even 
consider moving their operations to a country where 
obtaining regulatory approval is quicker than else-
where. Current estimates suggest that it take five years 
for a product in the health-care field to move from the 
laboratory to the market. Products not requiring regula-
tory approval can be exploited quicker, although even 
here it could take at least 3 years. 
Are project managers in biotechnology generally 
aware of the Community policy instruments available 
for project support? 
21. Literature produced by the Commission des-
cribes these projects and the Vademecum of contract 
research in particular is a most useful document in this 
regard. If there is a weakness in the awareness of bio-
technologists in regard to Community funding it is 
because of the way such literature is distributed within 
Member States. Perhaps more attention should be giv-
en to this. 
The UK's Protein Engineering Programme 
22. This managed Programme involves the funding 
by the Biotechnology Directorate and by four industrial 
companies of research projects in seven universities. 
The supported research is broadly divided between the 
production of new or improved proteins which can be 
used in health-care, as industrial enzymes or for other 
purposes. Together the companies concerned will pro-
vide about £0.5 million towards a £2 million programme 
over 4 years. Protein engineering is a multidisciplinary 
field with many potential applications. The programme 
being supported by the so-called 'Protein Engineering 
Club' includes not only basic research but also work 
that is of more immediate relevance to industrial 
needs. 
Discussion 
23. Dr. POTTER was asked, whether joint ventures 
were a way out of the problem of the 'missing link' in the 
application of biotechnological research which in Eu-
rope had fallen miles behind the USA. Dr. POTTER 
agreed that this was so and said that he would like to 
see a wider spread of companies and academic centres 
working together. However, he pointed out the difficul-
ties in organising such ventures. Joint ventures exist 
already but the cooperation should start at a precompe-
titive level. 
24. Is there a European basic research and, if so, can 
we use it to our benefit in competition with Japan and 
the USA? 
25. Dr. POTTER answered in the affirmative and 
explained that European research is very strong with as 
high a quality as that in the US and Japan but research 
in these two countries is better organised. 
26. Dr. POTTER was asked if there were any other 
programmes similar to the UK engineering programme 
which he had mentioned earlier, and whether the Com-
mission's programme of some 55 million ECU could be 
compared to the ESPRIT programme. He replied that 
this could lead to something like ESPRIT, but the most 
important thing for the moment is to bring companies 
together. Companies have to gain the confidence to 
work together. In the UK there is a directorate develop-
ing this cooperation. and something like this is needed 
at European level. However, patience will be needed. 
The crucial thing is project selection and therefore the 
project manager is very important. If you want to create 
common research amongst universities and companies 
which is not leading to their particular benefit and profits 
you need special arrangements. Many companies do 
not have this aim. 
27. One possibility for progress is the creatior of a 
demand in the EC countries in some biotechnological 
areas such as the 'orphan drug' system, mentioned by 
Dr. THOMAS, where European money and research 
could be concentrated. This could be mobilised for bas-
ic and applied research. But there are many problems 
with this. 
' 
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28. Concerning the Commission's proposal for the 
exclusion of small companies from anti-trust law, Dr. 
POTTER said that while some small firms were aware 
of this, many others were not. 
29. There is an increase in research which is not 
published but if a company wants to go to an institute 
offering money for research, it would be difficult for the 
academic department to turn it down. This can lead to 
difficulties because there will be less publicity for the 
results, which is indeed a problem for the cooperation of 
universities and companies. Mr GAUTHIER who asked 
the question thinks that this problem is mainly a disad-
vantage for young doctors who need to publish. 
30. Dr. POTTER's opinion about the brain drain from 
Europe to the USA is that the USA appears more attrac-
tive and offers research at a high level. During the dis-
cussion it was mentioned that the European language 
problem is a further obstacle for working together in 
Europe. 
3. Prof. Dr. MARCONI (ENI, Italy): 
European companies and the marketing of 
biotechnology: 
the field of pharmaceuticals, 
and, Dr. VANDENDAEL (EFPIA), 
pharmaceuticals in Europe 
31 . The fields in which use is made of biotechnology 
may be divided as follows: 1) Food 2) Agriculture 3) 
Energy 4) Pharmaceuticals 
32. After the discovery of recombinant DNA techni-
ques in 1973 forecasts have been made in many quart-
ers about the future development of this science. They 
converged on two points: 
-- biotechnology will be extensively developed 
- initially the field in which this development will be 
most apparent is pharmaceuticals, or more gener-
ally human health care. In order to judge future 
developments in biotechnology one should pay 
attention to two different types of product: 
- products of 'classical' fermentation, such as 
antibiotics and enzymes for therapy and clinical 
diagnosis, and 
- products of ·new' biotechnologies, such as re-
combinant DNA techniques or cellular fusion. 
These two categories are not only the result of a 
historical development but also reflect the present 
situation . 
33. While Europe holds quite a respectable position 
in the field of conventional fermentation, it lags behind 
the United States and Japan in the field of the new 
biotechnologies. This is also mentioned in the study of 
the US-OTA (Office of Technology Assessment). 
3'1. One reason for the European weakness in new 
technologies can be seen in the lower expenditure in 
biotechnology. The sum spent by Europe on education 
is about 1.7% of GDP (as an average). US expenditure 
is 2.4%, and the Japanese spend 2.1% of GDP. 
Between the various Community countries the expendi-
ture level ranges from 0.2% to 2.4%, the highest level 
being that of the Federal Republic of Germany, although 
even here it cannot be claimed that new biotechnology 
has been developed in the American way. 
35. In 1972 the German BMFT (Ministry for Research 
and Technology) had already recognised biotechnolo-
gy, together with data processing and telecommunica-
tions as one of the key technologies for the future. The 
investments were channelled mainly to the GBF (Gesell-
schaft fur Biotechnologische Forschung) in Brunswick, 
one of the best equipped biotechnology research insti-
tutes. Heidelberg is the site of the EMBL (European 
Molecular Biology Laboratory), which has one of the 
largest data banks of nucleic acid chains, although com-
mercial results have been slow to emerge. It is not the 
lack of investment but the rigidity and inflexibility of the 
German scientific system, which is responsible for the 
delay in the development of biotechnology in Germany. 
The reasons for Europe's delay in that field compared to 
the United States and Japan is clearly expounded by'an 
American formula: lack of government interference, 
total commitment of staff, possibility of personal gain 
lor academic staff. 
36. The Japanese formula for success in biotechno-
logy is completely different and based on extensive 
government intervention which encourages fruitful 
cooperation between universities and industry. This is 
the core of the problem: how to establish closer cooper-
ation between academic and industrial research. The 
solution cannot be based on the models used in USA or 
Japan, because of the different socio-economic struc-
ture of the three systems. There are other measures 
which must be taken both at national and Community 
level. A frequently heard complaint is the lack of tax 
incentives for research in most Community countries, 
which has a detrimental effect on the availability of 
capital. 
37. The incentive which induces American savers to 
invest is not a passion for new knowledge, but the lower 
rate of taxation for these forms of investment. To give 
an idea of the sums involved: the Federal Agencies in 
the US- spent $511 million on biotechnnology research 
in the period 1982-1983, whereas the funds placed at 
the disposal of the UK Government for the same period 
amounted to $116 million. 
38. At Community level, a solution must be found to 
another serious problem affecting biotechnology pro-
duction in Europe: the cost of raw materials (often this 
amounts for 60% of total costs). Most products of bio-
technology are based on the cultivation of micro-organ-
isms which require large quantities of carbohydrates 
(sugars), as substrates. European producers are at a 
disadvantage compared to competitors from outside, 
since they must buy the substrates at the prices dic-
tated by the Common Agricultural Policy instead of 
world prices, which are considerably lower. 
39. Another difficulty faced by the European pharma-
ceuticals industry is the absence of harmonised rules on 
biotechnology research and on the approval of drugs. 
Unless these problems are resolved, it will be difficult for 
Europe to stay in the race, despite the strength of the 
pharmaceutical industry, which is able to penetrate 
international markets: on average between 50-70% of 
the output is sold outside Europe, as opposed to 30-
40% for American industries and 2-7% for Japanese 
industries. 
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Dr. VANDENDAEL (EFPIA): 
Pharmaceuticals in Europe 
40. Despite ever-increasing advances made in the 
field of health, the diseases which remain after the first 
pharmaceutical revolution and which are not ·likely to be 
solved through traditional methods of research remain 
numerous. 
4 1 . Increased knowledge of the intricate mechan-
isms of cells gives some hope. Traditional pharmacolo-
gy could be compared with trying thousands of different 
keys in the lock to an unknown mechanism. 
42. There is a long-term interest in sustaining re-
search in chemistry. In order to be successful in this 
field a certain number of conditions must be fulfilled. A 
serious lack of research applications in industry and of 
collaboration between industry and universities is felt in 
Europe. Moreover. there is a financial problem. The risk 
involved is too important for Europeans because of the 
absence of a uniform market. A prerequisite would be to 
give a European dimension to this industry; a dimension 
comparable in volume to that of the United States at 
least. 
43. Dr. VANDENDAEL and Dr. MARCONI were an-
swered questions about the position of the Soviet Union 
and Europe. 
44. It is difficult to assess the position of the Soviet 
Union because they are very secretive and publications 
are few. 
In comparison with Europe, the USA doubled and the 
Japanese tripled their industrial production during the 
last 15 years. During the last 20 years the rate of spe-
cialisation fell to 14% in Europe, but rose to 65% in 
Japan. The pharmaceutical industry although born in 
Europe could not escape this development. 60% of all 
medecines still come from Europe, but the actual mar-
ket is the result of decisions taken during the last 20 
years and this is inadequate for the future. Only 36% of 
the medecine which was developed in the 70's and 
which will determine the market till the year 2000 came 
from Europe. Obviously Europe is not sufficiently innov-
ative in order to hold its position. 
45. Opposing the view of Mrs VIEHOFF. Dr. VAN-
DF::NDAEL mentioned that there are three companies 
which are researching into Malaria. Furthermore Dr. 
VANDENDAEL did not know of any interactions be-
tween companies which want to keep some discoveries 
secret. In general keeping such secrets is not possi-
ble. 
46. He also statc~d that monoclonal antibodies are 
not only a luxury for an early pregnancy test but they are 
very important in the field of diagnosis and therapeu-
tics. 
4 7. Finally, some arguments were stated concerning 
the problems relating to patent laws: 
- a 'periode de grace en matiere de brevet' was men-
tioned; this refers to a period of 6-18 months 
between the publication of research and the subse-
quent patent demand: 
- there are big differences between the different types 
of patents, for example. in regard to whether a living 
organisms can be patented: 
- the proposals of the EC are not perfect, but they can 
be an important element in allowing Europe fully to 
develop its potential on the international market. 
4. Prof. Dr. VAN MONTAGU (University of Gent, 
Gent, Belgium): 
European companies and the marketing of 
biotechnology: 
the field of agriculture and food processing 
48. He gave a detailed statement on the use of 
recombinant DNA techniques in plant genetic engineer-
ing and listed five fields of work, where there will be 
rapid developments. 
49. Firstly. new plant cultivation derived from the new 
DNA techniques would have a higher nutritional value 
and be resistant to insect attack. In five years genetical-
ly constructed plants could be a reality. 
50. Secondly, the recent breakthroughs in the under-
standing of plant molecular structure could lead to 
'diagnostic kits' for testin-g plants. 
51. Thirdly, soil could be genetically improved to con-
tain built-in features such as fungicides and insecticides 
and be more growth promoting. 
52. Fourthly, recent breakthroughs in computer mod-
elling {particularly in Belgium) would lead to enzyme 
engineering. 
53 r,fthly, the propagation of plants would no longer 
be a 'hit-or-miss affair', new knowledge would mean 
plant propagation could be more certain and produc-
tive. European enterprises making biotechnoiogical 
products have been successful but they have not 
enough capacity. 
54. The problem for Europe in creating this 'Brave 
New World' was the interest being shown by European 
Industry. UNILEVER was a leading force in biology tech-
niques but seemed not to be interested in recombinant 
DNA, already the US companies MONSANTO and 
DUPONT were dominating the field with vast resources 
being earmarked for developments. Whilst Dr VON 
MONT AGU admitted that BAYER had already invested 
in the Max Planck Institute in Cologne and BASF in the 
University of Heidelberg there was an urgent need for 
greater investment by European companies. E.urope 
still dominated such areas as enzyme production 
through companies such as NOVO (Denmark) and GIST 
(Holland) but the Americans were catching up fast. 
Conclusion 
55. The problem for Europe was that research teach-
ing was better in the US. Vast armies of graduate stu-
dents were concentrated at STANFORD, MIT and other 
specialist centres and were not dispersed in small 
research teams such as in Europe. There was an over-
riding need to interest industry directly in the promotion 
of research on the widest possible scale. 
Discussion 
56. In the subsequent discussion Dr. VAN MONT A-
GU gave some information about the gene-banks. The 
gene-banks which are available at the moment concern 
a collection of seeds and organisms collected from all 
• 
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over the world. For example there is a bank of 65,000 
rice seeds in the Philippines which is sponsored by the 
World Bank and the FAQ; another important bank is in 
Fort Collins in the USA. A problem for the international 
organisations could be private seed-banks. They 
should be available to every research institute or organ-
isation. 
57. The research done on recombinant genetics 
requires a lot of highly skilled know-how and much 
investment. Many parts of the genes have been chemi-
cally engineered and therefore it has to be considered 
as a chemical industry and the legislation should be the 
same as the legislation for chemical products. 
58. If progress is to be made in that type of research 
the industry must have financial or other incentives for 
development. This could mean that genes would not be 
freely available as firms envisage breakthroughs which 
would give them a competitive advantage over similar 
firms. 
59. Which products will soon be available for use on 
the market, particularly in the Third World? Once the 
relevant genes have been developed, techniques are 
such that the discovery can have a practical agricultural 
application within five years. Large plantations are to be 
set up in the US and the Third World, for tobacco and 
cotton production, for example. Unfortunately however, 
the number of current projects is limited. 
60. The major problem which biotechnology has to 
solve is disease control and reorientation because of 
over-production in US and Europe. A lot of biotechno-
logical material produced by agriculture will be used for 
new industries producing fine chemicals. 
61. Two additional problems, which the Community 
has to solve were mentioned. 62. Firstly, in Germany, it 
is necessary to have special agreement for the release 
of micro-organisms into the environment because of the 
possible negative environmental impact. Hence Europe 
should try to harmonise conditions in the Community for 
plant molecular-biology and release of micro-organ-
isms .. Dr. VAN MONTAGU stated that, while we have to 
ensure that regulations protect our society, this must be 
done as rationally as possible; institutions must ensure 
that bureaucratic delay is kept to a minimum. 
63. Secondly, the problem of risk-assessment in 
research: Dr. VAN MONTAGU outlined the limits to 
current knowledge and appealed for the authorities to 
take account of scientific opinion. A solution can only 
come through experience and the universities and 
industries conducting research must be aware of the 
risks involved. The universities are responsible for most 
of the new discoveries in the field. However, stronger 
links must be developed between these research bodies 
and the production agencies. The universities and small 
companies are necessary but if the advantages of bio-
technology are to be realised larger companies and 
institutions must become involved. 
64. Finally Dr. VANDENDAEL made a statement con-
cerning the problems encountered by smaller compan-
ies. Much of their research is duplicated and few will 
survive whilst they concentrate on the same projects. 
He pointed to the high risk nature of the industry and the 
length of time between investment and results which 
were far greater than in, for example, the electronics 
industry ('Silicone Valley n'est pas la meme chose que 
Siliclone Valley'). The primary question here is one of 
finance. 
5. Prof. Dr. BERENDSEN (University of Groning· 
en, The Netherlands): 
The relationship between biotechnology and 
information technology 
Introduction 
65. Dr. BERENDSEN began by speaking about theo-
ries on the use of engineered proteins to construct 
information processing devices, called biochips or mo-
lecular computers. These theories are still rather specu-
lative. 
66. A somewhat related development is the biosen-
sor in which, for example, engineered enzymes or mon-
oclonal antibodies, can be used in field effect trar.sistors 
to produce sensors for biochemical and medical use. 
Here biotechnology can have its impact on information 
technology. 
67. What Dr. BERENDSEN concentrated on in this 
report, however, is the impact of information technolo-
gy on biotechnology. 
Biotechnology and information technology 
68. The basic question here is: can a protein be 
designed for a specific purpose? This depends on 
whether we can make a reliable prediction on the basis 
of all the knowledge already available. If we can predict 
from a sound theoretical basis the property of a protein 
it would be possible to go a step further. Then it would 
be possible to design proteins for very specific pur-
poses, for example for catalysts with specific reactions 
in different industries. 
69. The next decade will show us what is possible 
and the prediction of functions and structures of biolog-
ical molecules on theoretical grounds will require com-
puter powers much more powerful than those presently 
available. The United States is pushing its computer 
industries (especially the supercomputers) because it is 
worried about falling behind Japan. 
Recommendations 
70. In the future biotechnicians will have no need for 
supercomputers with general powers. Actually, a new 
kind of 'specialist' computer is beginning to be devel-
oped. In biotechnology specialised computers are 
needed which work very fast and here Europe could 
take the lead. 
71. A rational design of biotechnology processes (i.e. 
structure-function relations, molecular structures) re-
quires advanced user-computer interaction: biotechno-
logy needs extensive data bases with high-level sup-
porting software, intelligent biomolecular work-sta-
tions, and super-computers with specialised software. 
72. Innovations in information technology required 
for biotechnology include, in order of priority: 
(i) special purpose computation devices that exceed 
the capabilities of super-computers, for prediction of 
macromolecular properties; 
(ii) advanced fast high-resolution graphics with stereo 
imaging; 
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(tii) expert systems related to data bases, 
(iv) man/machine interfaces including ·teeling· (touch 
with force response). 
73. The position of European expertise on graphics and 
computational software on biomolecular problems is 
comparable to that in the US and Japan. There are 
excellent research centres in the UK, Germany, France, 
the Netherlands, Belgium, Sweden and other countries; 
some have leading positions in the world. For central-
ised facilities and for organisational purposes the Euro-
pean Molecular Biology laboratory (EMBL) in Heidel-
berg is a suitable choice. However, the lack of financial 
aid necessary for modern laboratory equipment will 
cause Europe to fall behind the US. On the other hand, 
while European industries are not able to catch up in the 
super-computer market, Europe could strengthen its 
position in the still open market of special purpose 
devices. 
7 4. It is necessary for the European manufacturers of 
computers to be independent of the operating system 
and network standards of the large American computer 
firms (notably IBM. DEC), if they want to play a central 
role in the future. Furthering the active participation of 
Sweden, Norway and Switzerland would lead to a low-
ering of dependency on the USA 
Considera~ions 
75. The success of innovative biotechnological de-
velopments is dependent on advances in the theory of 
the functional properties of biomolecules. Products of 
this advanced technology can be applied in the mean-
time leading to unprecedented new products and pro-
cesses in the chemical and pharmaceutical industries. 
76. The basic problem of biotechnological designers 
in predicting the properties of a possible new product in 
advance. This can only be solved if the vast amount of 
information, obtained by advanced computer methods, 
is readily available to research bodies (universities, 
institutes etc.) 
77. Until now, the necessary technology for biotech-
nological predicting functions has only been available in 
American and Japanese super-computers. A concerted 
European effort. however. could bring about the devel-
opment of special integrated hardware/software ma-
chines with more specialised abilities for biotechnology 
along with reduced production costs. Design should be 
rationalised and the application of these designs must 
be reliable. 
78. The creation of the EMBL in Heidelberg is a step 
fonnard but it is only one of many possible options for 
the development of a biotechnological infrastructure. 
Discussion 
79. Dr. BERENDSEN said that there are already 
European facilities for developing special computers 
and once again he stressed that Europe should not 
develop supercomputers because the US and Japan 
have been developing them for 10 years. 
30. It was mentioned that in Toulouse, French and 
otner European specialists are organising a European 
computer centre in order to make a new European 
supercomputer. Dr. BERENDSEN did not agree with 
this. He added that specialised computers can also 
have a large variety of uses. 
81. Modern sciences need interdisciplinary workings 
but cooperation is rather difficult, because those people 
who have to work together are not used to this cooper-
ation and to bring them together needs a special 
effort. 
82. The Commission asked for the views of Dr. BER-
ENDSEN on the scale of resources needed for the con-
struction of special purpose computers and whether 
Europe should work together with the USA. Dr. BER-
EN OSEN answered that these activities should not be 
on a worldwide scale. At the moment Europe is still 
ahead in specialised computers and in software devel-
opment. There is no reason to fall behind the rest of the 
world. We should cooperate all over the world but we 
should not become dependent. The supercomputers we 
have in Western Europe come from the USA. At the 
moment we have about ten. In Delft, NL, a specialised 
computer for nuclear questions is being developed, oth-
ers are under development in Italy and Paris, and for 
biotechnological purposes one is being developed in the 
United States. In Heidelberg research is not concen-
trated on the development of computers. However, the 
present director intends to develop this field. 
rs. Dr. YOXEN (University of Manche£iter9 rn<.): 
Changes in industrial structure - and bio~ 
technology assessment. 
83. Policy for biotechnology may tH9 considered and 
developed at regional, national and international levels. 
International activity, such as that carried on within the 
European Economic Community, tends to be concerned 
with the harmonisation of regulations and the creation 
of a unified market, support for pre-competitive collabo-
rative development programmes and the selective sup-
port of strategic research areas. 
84. With the development of biotechnology one has a 
choice between three different kinds of policy -- the 
laissez-faire policy, a dirigiste policy, and a social envi-
ronmentalist policy. 
85. The first of these is most evident in the United 
States, where the emphasis has been on creating the 
right fiscal conditions for research-based entrepreneur-
ship. This has led not only to the creation of a significant 
number of small new biotechnology firms. but also to 
radical restructuring of large, well established compan-
ies, with the economic ability to invest heavily in stra-
tegic research centres. 
86. An advantage of this approach is its dynamism: it 
does certainly promote change. The disadvantages lie 
in what is taken for granted. It can cause the decline of 
much existing, inefficient industry, which may have sev-
ere effects in particular regions. It does not lead to the 
pre-competitive collaboration pioneered so effectively 
in Japan. 
87. Many countries have preferred a more interven-
tionist approach to innovation, with a greater degree of 
planning and directed investment. The emphasis is 
much more on sectoral planning and on the coordina-
tion of effort, nationally or internationally, and much less 
on small research-intensive companies and on tax relief 
for venture capital. The advantages here are more high-
ly organised programmes of research and investment 
plans which allow a degree of technology assessment. 
ThP, disadvantages could be that the whole exercise 
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can become very bureaucratic. Similarly, the discussion 
and technology assessment can be rather pointless, 
without the means or the political will to act on them. 
88. The ·socialist-environmentalist' approach is 
clearly intended to alter the balance of economic power 
and to introduce new values, such as those of the envi-
ronmentalist movement. Probably it is at the regional 
level that it is likely to work best. 
89. Its disadvantages are that it is relatively new and 
untried; it is obviously politically contentious and not 
easy to apply in a field that clearly depends on entre-
preneurship in one form or another. 
90. Dr. YOXEN'S conclusion from the above would be 
that we need in the European context is a diversity of 
approaches to innovation, even though his own prefer-
ence is for the 'specialist-environmentalist' approach. 
91. There is a clear need for a large home' market for 
the products of European companies. Since relatively 
few biotechnology products are actually on the market 
as yet. there is still time to act here. 
92. But innovation is as much a process of selection 
and rejection as it is of the invention of new ideas. All 
kinds of product ideas fail or are abandoned because 
they do not fit the commercial priorities of major produc-
ers. A common example is 'orphan drugs·. This sug-
gests the idea of soliciting from researchers in Europe 
ideas which have falien by the wayside, or from unpro-
fitable areas, like vaccines or occupational medecine, 
for support witt1in a special Community funded pro-
gramme. 
93. Need for TA (Technology Assessment): 
(i) TA is performed by an prudent company when it 
assesses a product for a market; 
(ii) TA as a general economic and social evaluation of a 
particular technology, - this is what is meant by the 
term here in biotechnology; 
(iii) TA being done by groups of workers and trade uni-
ons who want to assess the product and production 
strategy of the company they are working for. 
Tl1e European Foundation for the Improvement of Liv-
ing Conditions, based in Dublin, is involved with the 
second point. They are developing a research plan for 
TA and Dr YOXEN's group in Manchester is linked with 
this Foundation. · 
94. The pharmaceutical and seed industries are typi-
cal examples o'f technologies which need TA. There is 
little data on the potential impact of products based on 
biotechnology in Europe, so Dr YOXEN concludes with 
these points: 
(i) Industrial involvement and university research 
woulrl be irnprovp,d by having stricter rules on the 
disclosure of commercial involvement by those who 
are involved. The effects of universities taking equi-
ty ownership in companies in the biotechnology field 
have to be considered carefully. This practice alrea-
dy exists among some British universities but its 
benefits are disputed. 
(ii) Products of great social value might fail in some 
people's economic assessment. It is clear that there 
are, within the field of biotechnology, a number of 
products of this kind, but if you consider innovation 
as a highly selective process you have to choose the 
which ideas should be retained and have their devel-
opment subsidised. In that particular area someth-
ing like an 'orphan drug' system has to be em-
ployed. 
(iii) There are a number of areas, such as the effects of 
economic concentration in the seed industry, which 
need much more study. Whilst some commentators 
have tried to predict the effect of 'new seeds' being 
marketed by large agrochemical concerns, much of 
this comment is somewhat speculative, and based 
on US or non-European agriculture. This question is 
exactly the kind of thing that an Office of Technolo-
gy Assessment attached to the European Parlia-
ment could examine. This shows that an 'OT A' for 
the European Parliament would be a very positive 
development. 
Discussion 
95. Concerning the role of FAST and Technology 
Assessment on the national level, Dr. YOXEN thinks 
that the new European Institution has to complement 
the activity of FAST. It is difficult to say how an Office of 
TA should work. Governments have preferences for 
national questions and interaction has to be considered 
at the European level. 
96. Dr. LINKOHR who reported on TA in Europe, 
considers that the development of a European TA 
necessitates a common European culture, i.e. agree-
ment on a common technology assessment can only 
stem from common values and aims. So he is of the 
opinion that we should strengthen national TA, but we 
should make it more transparent in order to initiate a 
discussion on the European level which would lead to 
the development of a European view of new technolog-
ies. 
97. Dr. YOXEN also recognises that national differ-
ences exist and that there must be a forum to stimulate 
debate and create an overview of national situations. 
The impact of the FAST teamwork on biotechnology 
was raised by Mr CANTLEY, speaking on behalf of the 
Commission; he emphasises that the work of the FAST 
team has been integrated into the programmes, which 
are now being implemented. In fact, three members of 
staff had been transferred from the FAST team into the 
concertation unit of biotechnology precisely to help with 
that implementation. The FAST recommendations had 
to be integrated with the new research programmes. 
98. Concerning the seed industry within the new 
FAST programme, there is a specific subprogramme on 
the use of the renewable natural resource system. On 
this specific topic of genetic diversity, and of course the 
seed industry, FAST intends to organise a major world 
conference on biological diversity and property which 
perhaps should be co-financed by the European Parlia-
ment. 
99. At the end of the discussion some questions 
about the negative impacts of biotechnology were 
raised. Mr. HARLIN asked for a list of criteria concern-
ing negative effects of biotechnology which are ac-
cepted by the scientists. As regards the time needed for 
technology assessment there exists no average time 
lag. Some evaluations are done briefly and some need a 
long time. 
... 
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Part II: 
The impact of biotechnology 
1. Dr. MAHLER (NOVO, Denmark): 
Risks and dangers involved in research and 
application of biotechnology - efforts to har-
monize legislation 
100. There are already a lot of institutions which are 
working for safety and regulation in biotechnology: 
- WHO. which held a meeting in Dublin; 
- OECD, which is preparing a report; 
- Coordination Committee between the chemical in-
dustry (represented by SEFIC), the food industry 
(represented by CIIA), enzyme manufacturers (re-
presented by EMFEP), the pharmaceutical produc-
ers (represented by FPI) and the agrochemical 
industry (represented by KIFAB). 
They want to present to the EC Commission a uniform 
approach to biotechnology from their point of view at 
the end of 1985. 
Risk assessment and guidelines 
101. Europe needs conceptual information and here 
it can learn from the US experience in biotechnology. 
Competition and safety have to be seen in the content 
of this being a question of efficient decision-making 
where you accept new products and applications of 
biotechnology knowledge without incurring unaccepta-
ble risks. 
102. The risk of the unknown is always there and we 
deal with it by unspecific testing. In risk assessment it is 
important to involve all the relevant experts and by 
using headlines and distributing documents the risks 
can be avoided. If the various experts involved in pre-
paring the guidelines or 'Points to Consider' type docu-
ments for the particular kind of genetic transfer have 
done their job, these documents will reflect all the risks 
which have to be recognised as potential or objective 
risks even if they are not novel. Each point to consider 
corresponds to a risk, and by using the document as 
guidance. all risks can be avoided. It should be men-
tioned tllat only ttie transfer of genetic material across 
species barriers is considered here as new biotechnolo-
gy, since by definition only such transfers do not already 
produce fertile hybrids in nature. Risk assessment 
means moving forward with caution: potential danger 
will eittler disappear or become controllable, that is able 
to be evaluated and handled. While the science may not 
be revolutionary, some of its applications may yet be. 
103. Ten years ago some 140 scientists met in Asi-
lomar (USA) for a moratorium to discuss guidelines for 
biotechnology. The call for a moratorium was followed 
in 1976 by the first version of the NIH guidelines, which 
were mandatory for NIH funded research and voluntari-
ly followed by everybody else. The principles of contain-
ment and scale limitations stated in the NIH guidelines 
were soon adopted in other countries, and when the 
NIH guidelines were subsequently relaxed, these relax-
ations were, for the most part, adopted too. The step-
wise approach to less restrictive NIH guidelines has 
now been taken to a point where the majority of recom-
binant DNA experiments in the US only require local 
committee approval, and where the original and some-
what arbitrary 10 litre-scale limitation has been re-
moved, permitting NIH to authorise large-scale manu-
facture. This development from very strict to more 
relaxed guidelines can be seen as a sequential ap-
proach, each step being the result of accumulated 
experience which did away with the fears expressed at 
Asilomar. 
104. Certainly there was some over-optimism in the 
USA which resulted from not paying enough attention 
to research risks. Ten years of experience tell us that 
the guidelines developed combined with existing legis-
lation are adequate for occupational health, safety and 
environmental protection. Further, the majority of re-
search is applied research with an empirical base and 
not fundamental research without empirical datas of 
risk assessment. 
105. An important aspect in risk analysis is the differ-
entiation: 
- between kinds of organisms and micro-organisms: 
for example, plant elements and human elements 
are less well understood from a genetic expression 
and control point of view; 
-- by the level of understanding, because the only real 
risks are that we do not know what we are doing; 
- between contained and released users. on the pro-
duction basis; 
- between a use of the organism itself and of a part of 
it; 
- between an extract and a compound from the 
organism. 
106. A differentiated risk analysis could imply ttrnt 
some recombined DNA uses are considered as be-
longing to traditional old biotechnology so that they can 
be used routinely. 
legislation and harmonisaticn 
107. So far very little legislation has taken place in 
Europe or anywhere else. Tl1e UK and Sweden have 
expanded their occupational safety and health legisla-
tion to cover specifically notification of recombinant 
DNA work, and the Netherlarids has similar intentiohs. 
In Denmark enabling legislation has been drafted. which 
may result in Denmark becoming the first country to 
regulate agricultural and industrial applications of new 
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biotechnology. Sweden on the other hand may abolish 
some of its present legislation. Apart from this. it would 
seem that the European countries have followed the 
recommendations by the European Science Founda-
tion, the Council of Europe and the Council of the Euro-
pean Community to use NIH type guidelines, a notifica-
tion procedure and refrain from introducing legislation 
at this stage of development. It would still seem possi-
ble to save Europe from divergence. 
The competitive position of a country in regard to legis-
lation is determined by its ability to keep pace with its 
industry in all phases of recombinant DNA develop-
ment. When companies are ready for large scale pro-
duction, national authorities should be ready to assess 
and approve the production plans. For plants, one has 
today according to international convention to choose 
between patent protection and plant variety rights pro-
tecting only the seeds. In the European Patent Conven-
tion, however. plants and animals are exempted from 
patentability. Plants can be patented in the US, Germa-
ny and France. Plant variety rights are found in many 
countries. but they will not serve the purpose of protect-
ing recombinant DNA plants effectively. Harmonisation 
would seem to be possible in an area where no signifi-
cant national legislation exists, and where the contents 
of the guidelines for recombinant DNA work were 
essentially the same everywhere. The main bottlenecks 
are to be found in European countries without such a 
tradition for harmonisation. With good reason Europe is 
often seen and dealt with by the US and Japan as a 
number of separate and different countries. It should be 
understood of course that harmonisation must be glo-
bal in order to satisfy the purpose of effectively advanc-
ing the new biotechnology. Consequently European 
harmonisation is only one step, although a most impor-
tant one, towards this goal. OECD harmonisation 
seems the most likely higher level attainable in the near 
future and a global harmonisation would involve the UN 
and the WHO in the final phase. The EEC directive on 
information procedure for technical standards and reg-
ulations may also promote harmonisation. 
108. A final remark: Human gene splicing will be a 
problem in the future, but the only real risk may be the 
irrevocable reduction of the genetic diversity within and 
among us 
DiSCOJS$i01"D 
109. During the discussion the question of the risks 
of biotechnology was raised. There is a danger that 
far-reaching changes caused by biotechnology may 
also involve irreversible damage such as happened with 
hydrochlorides. Through ever-increasing understand-
ing Technology Assessment may be continuously refor-
mulated. This does not mean that existing rules should 
be totaily alterPd. Improvements can be achieved by the 
inclusion of specialists and the public in the consultation 
process. This ;ilso involves ethical aspects of biotech-
nology. Thus philosophers and theologians have parti-
cipated in a report on the splitting of genes in the US. 
Furthermore it would be better to determine what are 
Hie needs and thP.n speak of investment. 
110. Concerning the problem of harmonisation of 
regulations. Dr. MAHLER referred to the advantages 
and disadvantages of acting at different levels (EEC. 
OECD). It is felt that harmonisation is a favourable 
development and should be as widespread as possi-
ble. 
111 . Concerning sanctions imposed on firms which 
ignore guidelines. it was stated that these guidelines are 
in general mandatory for government-sponsored re-
search, but they are usually adhered to by the. industry 
too. To conclude Mr FAIRCLOUGH (Comrrlission) 
spoke about the introduction of legislation which was 
considered by Dr. MAHLER 'as a result of application 
pull rather than science push'. But the basic problem of 
how to reach harmonisation remains. The question is 
whether we should proceed in this direction at EEC or 
OECD level. Do we adopt voluntary guideliness or 
should a general framework be introduced quickly? 
112. Dr. Mahler, in reply, considered that a formal 
framework .for consultation might be useful, but that 
informal discussions are now taking place. The Com-
mission should be aware of developments in this area. 
Consensus is necessary before any legislation is pro-
posed. This building of consensus may take place at 
various levels. In order to stimulate a balanced develop-
ment in the various OECD countries, the national gov-
ernments should introduce regulations in this field. This 
would prevent the establishment of a diversity of rules 
set up by by the industry itself. 
2. Prnt Dir. IP~P~Mffe\ TIHllE~m~ ~!Rl®S®alli©h C®l?il~li'® 
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113. Addressing the issue of the future development 
of biotechnology (B.T.) is extremely difficult unless one 
defines a narrow time range for projected and likely 
developments in this dynamic field. The impact of the 
new biotechnology is just starting to become apparent 
and it is expected to be significant. This is indicated by 
intensive public and private investment of capital and 
reorientation of research and development activities in 
many cases. Major rate-limiting factors in large scale 
applications are: 
- process engineering; 
- genetic and metabolic stability of engineered micro-
organisms or their products; 
- containment steribility and ecological effects. 
This implies that a vigorous further development of the 
biotechnology industry will rely on solving the above 
problems. Funding for supporting training and research 
and development projects in fields related to fermenta-
tion and engineering technologies is of key importance 
towards effective solutions. 
1 i 4. Concerning lroeaimil icsre, particular emphasis is 
given to hormones (endorphines, insulin, human growth 
hormone, somatostatin) and other bioactive sub-
stances. DNA insulin is a good follow-up case for mar-
ket studies. since it is now commercialised. De•1eloping 
vaccines for malaria etc., is a promising area for disease 
control and two major new markets are monoclonals 
and interferon. Another interesting aspect of future 
development in disease control is the introduction of 
molecular diagnostics. 
Chemi«:ais 
115. Although the traditional organic chemicals will 
be difficult to displace (for example, petrochemicals) 
biotechnology-based production is expected to have a 
visible effect on the chemical industry by the turn of the 
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century, contributing 10-15% to the overall market. In 
the longer run the dwindling global reserves of feed-
stock will necessitate the development of renewable 
sources. High-scale fermentation, using microorgan-
isms boosted by genetic engineering, is an obvious 
solution to the future shortages. Key features in a stra-
tegic approach regarding biotechnology and its role 
are: 
-- fundamental knowledge in cell metabolism and kine-
tics; 
- process engineering; 
- immobilisation and affinity techniques to increase 
efficiency of production; 
- effective means for securing genetic and phenotypic 
stabilities of the organisms in use. 
Agrofood 
116. Recent advances in gene isolation and transfer, 
suggest that important developments may appear 
soon. More than 90% of the human diet is based on 29 
crop species, 15 major vegetable and 15 fruit crop spe-
cies. These crops are obvious targets for DNA ap-
proaches to solving problems of plant physiology, 
development or physical factors. Main lines of activity in 
agrofood biotechnology are: 
- pest. disease and stress control; 
- enhancement of yield: 
- upgrading products: 
- animal production and protection. 
Classical approaches to these problems will probably 
become obsolete, for example, the chemical pesticides 
market will be superseded by the microbiological meta-
bolic products. In the long run biomass utilisation and 
chain-bioreactors will be of major importance. Pollution 
control and waste treatment will be most beneficial for 
society 
Conclusion 
117. Biotechnology is steadily going to increase its 
share of tt,e overall high-scale production in health, 
chemical and agrofood products including energy. This 
intervention is slow but cumulative. The anticipated 
social effects are significant although the time range for 
many achievements is hard to evaluate. 
Defining the role of Europe vis-a-vis this process is vital. 
•, Tt1us the determination or re-evaluation of strategies 
for a vigorous response at this transitional stage has a 
critical political and social bearing for the future. 
1 t During the following discussion the importance of bio-
tP.ct1nology for the energy sector was raised. There are 
c1 lot of problems which could be solved by biotechnolo-
gy but which are not yet recognised as being significant. 
for example. thP tertiary P.xtrnction of oil. lntRrP.~;t 
st1ould he tak£m in investment for d1s;idva11ced sector~ 
such as for specific problem areas in the Third World. 
21 
·I 
I 
.. 
.. 
• 
•.. 
PART Ill: BIOTECHNOLOGY AND INTERNATIONAL POLITICAL IMPLICATIONS 23 
---------------
Part Ill: 
Biotechnology and international political implications 
1. Prof. Dr. JUNNE (University of Amsterdam, the 
Netherlands): 
Biotechnology and consequences for chang-
ing relations between EC-USA, EC-Japan and 
USA-Japan 
118. Of the relations between the major trade blocks 
inside the OECD area, relations between the European 
Community (EC) and the United States will probably be 
the most affected by the application of biotechnology. 
The effects on the relations between the USA and 
Japan are less clear-cut and the effects on relations 
between the EC and Japan probably are only margi-
nal. 
119. Biotechnology will have a far-reaching impact 
on agricultural production. This will affect trade rela-
tions between the USA and EC in two ways: it will affect 
bilateral trade as well as competition in third markets. 
The USA has never really accepted the Common Agri-
cultural Policy (CAP). The EC, however, can point to the 
fact that in spite of CAP. the EC is the largest importer 
of US agricultural products. and that the USA realises r1. 
considerable trade surplus in agricultural trade with 
Western Europe (of about $6 billion annually). 
120. The EC is trying to limit the import of animal 
feed. About half the European imports of agricultural 
products from the US fall under this category. EC policy 
aims at the development of new plants which are rich in 
protein and can be produced at acceptable costs in 
Europe to replace imports. 
121 . In order to stimulate this development, the EC 
tried to put on a ceiling on imports of maize gluten from 
the US and started negotiations with the American Gov-
ernment in 1984. 
122. The US Government strongly opposed such a 
measure. The reason for the strong reaction can be 
better understood if the impact of biotechnology on 
food processing in the US itself is taken into account. (In 
the US, large quantities of sugar have been replaced by 
High Fructose Corn Syrup (HFCS) produced from 
maize. and HFCS replaces more than 2 million tons of 
sugar per year.) 
Effects on competition in third markets 
i 23. Besides being the largest importer of US agri-
cultural products, the EC is, at the same time, also the 
world's second largest exporter of agricultural products 
after the US. In many markets of the world, the US and 
the EC compete directly with each other. 
124. As a consequence, biotechnology will contri-
bute to increase surplus production both in the US and 
Europe. 
125. This happens at a time when the application of 
biotechnology, in many importing countries, may even-
tually help to reduce their food imports in the long run. 
This will take a long time in many developing countries. 
However in the Soviet Union and China, who have been 
major importers in the past, this application can be 
realised somewhat sooner. This would have conse-
quences for relations between the EC and the USA in 
two ways: (a) it would increase surplus stocks that 
would have to be sold in other markets, thus increasing 
international competition, and {b) it would have an 
impact on the differing interests in East-West trade of 
the US and the EC respectively. 
126. Biotechnology will probably contribute to a con-
siderable increase of productivity in agriculture. As a 
consequence for agricultural policy, surplus production 
would increase to such a degree that it could no longer 
be financed. 
Consequences for technology transfor and scientific 
cooperation 
127. The US Government has suggested putting 
many biotechnology products on the COCCM list of 
strategically sensitive goods that must not be ex;:>orted 
to socialist countries. Since biotechnology can be used 
to produce biological weapons as well as detecting 
agents, sensors, vaccines and strategically interesting 
new materials, it is classified as of special relevance to 
the military. This may also have a negative conse-
quence on technology transfer from the United States 
to Western Europe and on international free scientific 
communication. 
128. A large area of potential European exports 
might fall under an expanded list, if the United States 
were to get their proposals accepted. American and 
European interests clearly diverge in this area. 
Consequences for relations · between the USA and 
Japan 
129. The US and Japan are also involved in a long-
standing conflict on agricultural trade. Japan is the 
country that is the single largest importer of American 
agricultural products (the EC imports more only as a 
group). Japan receives 15% of American agricultural 
exports, which constitute 40% of Japan's agricultural 
imports. 
130. The United States, however, is insisting oh a 
further liberalisation of Japanese agricultural imports. 
An expansion of agricultural exports is expected to 
reduce the tremendous deficit in bilateral trade with 
Japan. What role does biotechnology play in this 
regard? 
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131. As in the case of the EC, a large amount of 
Japanese agricultural imports from the US consists of 
feed grain. Developments in the field of biotechnology 
may help to substitute some of these imports by domes-
tic products (such as high-protein feed made from rice, 
straw or algae). Biotechnology will also help to develop 
higher-yielding rice varieties. It may also lead to some 
export of rice which would compete with American 
exports and lead to additional tensions in the relation-
ship with U1e US. 
132. However, agricultural products will increasingly 
be used as industrial raw materials. This will increase 
the demand for agricultural imports. A reduction of 
imports as a consequence of substitution by local pro-
duction will therefore be compensated for. 
133. In the long run, the rather complementary char-
acter of the United States' and the Japanese economies 
may even be strengthened by this development. 
134. Tensions may result more from applications of 
biotechnology in fields other than agriculture. In bio-
technology, a pattern similar to that which developed in 
microelectronics may occur; in this case, whilst the US 
economy excelled in the invention of new products, 
Japanese companies succeeded in optimizing produc-
tion processes for these very same products and then 
competed very successfully in the world market. 
Consequences for relations between the EC and 
Japan 
135. The relationship between the EC and Japan will 
probably be little more than marginally affected by 
developments in biotechnology. Those areas in which 
biotechnology may have an important impact on trade 
flows (raw materials, agricultural products) do not play a 
large role in bilateral trade between Japan and Euro-
pean countries. 
136. More than the field of bilateral trade, the export 
of capital equipment for biotechnological production 
processes to third countries may become an area of 
increasing competition. The EC and Japan are the most 
important capital goods exporters to developing coun-
tries. The more biotechnological production processes 
are introduced, the larger the demand for equipment in 
this field will be. Given the considerable experience of 
Japan in this field and the fact that it has every reason to 
boost research and development in this area. the Ewo-
pean market share in capital goods may come under an 
even greater thrPcit in the future 
Problems raised by the questions: 
- Dr. JUN NE said that despite the difficulty of predict-
ing the real impact of biotechnology on agriculture 
and world trade, some prognoses can be made. for 
example. on the increase of productivity, 
-- The most serious problem is overproduction. This 
can only be solved by reducing the amounts pro-
duceci since the surplus cannot be exported. The 
USSR will. in the future, come to be more indepen-
dent of cereal imports. The USA will probably insist 
that Europe reduces production because Europe's 
production costs are higher than those in the USA. 
All this would cause new conflicts bPcause there 
would be no further interest in the USSR and differ-
ences of interest between the EC and the US would 
become less acute. 
Dr. JUNNE gave some information about the US 
defense department and its programme to advance 
research in the field of biotechnology. Most of the 
uses of biotechnology are not in the field of arma-
ments, but in the development of new sensors, new 
material for aircraft, etc. or for vaccines for overseas 
personnel. There is no danger of biotechnology 
being used for weapons at the moment, but the 
possibility that it may have this capacity has led to 
much secrecy in development. The US defense 
department would like to include a lot in the COCOM 
list, because it is difficult to say which aspect of 
biotechnology may have military applications. 
- Concerning secrecy, it is difficult to keep secret 
information about biotechnological research be-
cause of the different forces which are working in 
this field, for example: 
- the patent rules which are important for compe-
tition. 
- the commercialisation of research, 
- the military potential, 
- the tendency to keep subsidised research in one 
country. 
Information control should be regulated at an inter-
national level. The OECD would be the best body for 
this. 
2. Dr. KUIPER (University of Amsterdam, Nether-
lands): 
US-European joint ventures: consequences 
for European export policy 
137. How do European companies in the field of bio-
technology come wittlin the ambit of US export con-
trols? This question is a great problem now and will be 
in the future, as internal US regulations on biotechnolo-
gy may also have consequences for European biotech-
nology firms as _ well. In order for this question to be 
answered it must be divided into three parts: 
(i) certain goods of US origin; 
(ii) certain US technical data; 
(iii) corporate (or personal) links to a company incorpo-
rated in the USA. 
138. In the first case, chemical and biological agents 
which have weapons applications are listed in the US 
Munitions List. Their exportation to all destinations is 
controlled under the US Arms Export Control Act. Since 
these controls are coordinated through COCOM they 
should not cause any serious problems to EC Member 
States, which normally apply these same controls. 
139. Secondly, certain chemical substances and 
most bacteria, fungi and protozoa figure on the US 
Commodity Control List (CCL). A so-called 'val;dated 
license' is required for their export to the USSR, its 
East-European allies, North Korea. Laos, Kampuchea, 
Vietnam, Libya and Latin American countries. This 
means that an individual export license · has to be 
obtained for every export transaction above a certain 
value. Sarne of these controls arn unilateral i.e. not 
coordinated through COCOM. 
140. Unilateral controls of exports to non-EC coun-
tries may have repercussions for European companies. 
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because re-exports from Europe to controlled destina-
tions are also controlled. In the most extreme situation 
this may lead to a European company having to request 
a re-export authorisation from the Office of Export 
Adminstration (OEA) in Washington D.C. 
141. In sµite or tt1e offensive aspects of US export 
and re-export controls, the actual problems with res-
pect to these controls may well remain limited, as long 
as the number of unilateral US export controls in the 
field of biotechnology is restricted. It seems that some 
biotechnological products and processes are going to 
be, or have already been, placed on the COCOM watch-
list, which may lead to their ultimate inclusion the 
COCOM prohibited list. As long as multilateral agree-
ment is reached on restrictions on biotechnological 
exports, trans-Atlantic friction can be minimized. 
Export controls on technical data 
142. Although virtually all Western countries have 
some kind of legislation which enables the government 
to classify patent applications which show a links with 
national security, the US is the only country in the Wes-
tern alliance to have, in addition, a regulatory system for 
the restriction of technology exports and re-exports. 
Other countries merely restrict the export of the pro-
ducts embodying the technology; the US also restricts 
the 'technical data' itself, insofar as it is 'directly and 
signficantly related to the design, production or utilisa-
tion in industrial processes' and not 'generally available' 
to the public. 
143. Export and re-export of technical data are 
defined so broadly in the Export Administration regula-
tions that if, for example, a Dutch engineer were to tell 
the participants in the biotechnology hearing some 
technical details about a biotechnology plant he had 
seen in Amsterdam and which was built with some 
technical help from the US, he would be re-exporting 
controlled technical data. Formally he would need a 
validated license for that. 
144. If one takes into account that more and more 
biotechnological know-how probably will be brought 
under the export restrictions of technical data, it is not 
fanciful to assume that serious problems might develop 
between the US and its European allies, if such restric-
tions do not obtain .. multilateral agreement. In the past 
the EC has protested strongly against US measures, for 
example during the pipeline controversy in 1982 and 
also criticised at that time the attempt to extend US 
jurisdiction over persons handling technical data by 
requiring specific clauses in private contracts. 
Persons subject to the jurisdiction of the United 
States 
145. The principal provisions of the Export Adminis-
tration Act of 1979, (as amended in 1985), which serve 
as legal basis for the regulations partly described 
above, give the President authority to prohibit or curtail 
the export of · any goods and technology subject to the 
jurisdiction of the United States· or exported by ·any 
person subject to the jurisdiction of the United 
States·. 
146. Although at present this standard definition is of 
little importance. since the obligations relating to the 
rn-export of controlled goods and technical data are 
incumbent on any person inside and outside the US. it 
may come back to haunt European corporations at any 
moment. The habitual regulatory definition includes 
companies incorporated outside the US which are 50% 
or more US-owned (in certain cases even 25% or more 
US-owned if the other share blocks are less than 25%). 
This would make a normal 50-50 joint venture between 
a US and a European company, even if it were incorpo-
rated in an EC Member State, into a 'person subject to 
the jurisdiction of the United States· for the purposes of 
US export controls. During the pipeline controversy this 
way of bringing companies incorporated in EC Member 
States within the ambit of US jurisdiction was roundly 
condemned as contrary to international law. 
Conclusion 
14 7. Although at present US export controls on bio-
technological products and know-how may not cause 
grave problems to the European industry in this field 
which has technological or corporate links with the US, 
there is a considerable potential for conflict if the US 
carries out its intention to introduce more sophisticated 
controls on these products and related technology and 
does so unilaterally. Indeed, if more sophisticated res-
trictions on exports to 'unfriendly' countries are 
needed, an effort should be made to achieve agreement 
within a multilateral framework. 
Mr. DOROUGH, Counsellor for Science and Tech-
nology of the U.S. Mission to the European Com-
munities: 
EC-US Relations in biotechnology 
148. On 31 December 1984, the United States pro-
posed a coordinated national framework for the regula-
tion of biotechnology. 
149. As an integral part of the proposal, US regula-
tory agencies committed themselves to seeking interna-
tional harmonisation on a whole range of scientific and 
technical issues such as test guidelines and good labo-
ratory practices. Much of the harmonisation which has 
already occurred in these areas is applicable to biotech-
nology. The EC commented favourably on this commit-
ment. 
150. Mr. DOROUGH called for a regulatory structure 
'which should be of sufficient transparency and clarity 
to avoifl the creation of technical barriers to trade and 
draw to the maximum extent possible on existing 
national regulatory practices'. Members of the commit-
tee were disappointed that Mr DOROUGH could not 
speak more widely on his Government's attitude tooth-
er points raised in the hearing. Unfortunately, Mr. DOR-
OUGH also gave no reply to the speeches of Dr. JUNNE 
and Or. KUIPER. 
3. Prof. Dr. Salomon (Conservatoire national des 
Arts et Matieres, Parin, France): 
Consequences of biotechnology for Third 
World countries 
1 51 . Despite the similarities amongst problems fac-
ing the Third World, there are great disparities in the 
situation of different countries. The possibilities offered 
by biotechnology. together with the attendant risks of 
distortion, must therefore be seen in the light of these 
disparities. 
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152. Unfavourable effects of biotechnology in Third 
World countries may be expected for tl1e following rea-
sons: 
(i) Because of its cost, its technical complexity, the 
scientific personnel it requires and the scale of the 
markets which undertakings must aim at, this 
research field is likely to increase the technological 
gap which exists between most Third World coun-
tries and the industrialised nations. In this field, the 
future seems unlikely to differ greatly from that of 
the pharmaceuticals industry. In addition to the dif-
ficulty of competing with multinational undertakings 
or smaller firms dependent on large-scale finance 
connected with risk capital, there will be the further 
handicap of the growing privatisation of research 
findings. 
(ii) The new products and processes developed in the 
industrialised countries will inevitably come into 
competition with the traditional products and pro-
cesses used in the less-developed countries, ren-
dermg existing qualifications and practices obsolete 
and, above all, displacing or even eliminating from 
the market products which constitute the only cur-
rency of exchange for many Third World countries 
- hence the threat of an increased balance of pay-
ments deficit, higher unemployment and even worse 
food shortages than at present. 
(iii) Concerning sugar, it must be feared that the grow-
ing consumption of fructose syrups and the replace-
ment of sucrose for industrial purposes and in food 
will lead to an increase in sugar cane stocks and this 
will lead to a crisis in the sugar industry in the tropi-
cal producer countries. 
(iv) Few Third World countries would be able to partici-
pate extensively in projects in ttie first category 
(genetic engineering or bio-engineering. recombi-
nant DNA techniques. cloning. etc.) whereas most ot 
them would be able to contribute to the transfer of 
the various applications of biotechnology. Develop-
ing countries which can master production pro-
cesses are described as the new industrialised 
countries and include Brasil, Mexico. South Korea, 
Taiwan. 
t 53 The selection and the transfer of biotechnolog-
ies ate clearly going to play a crucial role. This is a 
problem which is both economic and political. Genetic 
engineering involves costs as disproportionate as and 
disadvantages of the same kind as those involved for 
instance in robotics. On the other hand. the techniques 
connected with traditional biotechnology (fermentation 
1n solid and liquid media, compostage and recycling of 
waste, production of biogas, hydrolysis of cellulose and 
decomposition of lignite, etc.) could be substantially 
improved through research progress. For example, 
smaller and therefore less expensive production chains, 
introducing small-scale techniques as opposed to those 
aimed at the large-scale manufacture of amino acids, 
would also r1ave the advantage of protecting soils, 
reducing deforestation and monitoring the population of 
rural areas. 
154. How can the industrialised countries help to 
reduce some of the most urgent problems facing the 
Third World by means of their research in biotechnolo-
gy? 
By paying attention to the conditions governing the 
selection, transfer and adaptation of the new tech-
nologies. 
- By providing and seeking to reduce the unf avour -
able effects produced by the widespread dissemina-
tion of new products and processes likely to 
increase the economic vulnerability and dependence 
of developing countries. 
155. If a proper equilibrium is to be achieved between 
North and South it is in the interests of the industrialised 
world and the EC to ensure that the repercussions of 
biotechnology are not going to be exclusively negative 
for the Third World. 
Discussion 
156. In a statement Mr. SELIGMAN (MEP) proposed 
to organize a special conference on the specific prob-
lems of developing countries with the participation of 
the countries concerned. 
157. Data banks could be developed for information 
on animal and plant species. There is a need for highly 
qualified people in recipient countries who can make the 
most of this information. 
158. In answer to a question on racial engineering Dr. 
SALOMON said that although some work had been 
carried out in the United States this really could not be 
taken seriously. 
159. Finally Dr. SALOMON emphasised that in the 
Third World skilled technicians are more important than 
scientists who may be trained in recent 
techniques of biotechnology. 
4. Dr. MUNCK (Carlsberg Research Laborato-
ries, Copenhagen, Denmark): 
Industrial use of agricultural products in Eu-
rope and the principle, of agricultural refiner-
ies 
160. The increasing surplus of cereal grains (except 
maize) in the EEC causes a mounting economic problem 
with regard to financing export r~stitutions. Emergency 
aid to starving developing countries is one of the outlets 
for this surplus. 
161. The current situation of EEC tariffs and resti-
tuion payments for cereals, related raw materials and 
industrial products manufactured from them, is some-
what chaotic. 
162. However. for the citizens in the EEC many good 
reasons exist for maintaining a common agricultural 
policy. It gives us a basic self-sufficiency in many 
classes of food production, and contributes directly and 
indirectly in the order of 20-30% to the gross national 
products of our countries. Furthermore, fluctuations 
due to varying weather conditions etc. make it difficult 
to maintain the EEC's policy for self-sufficiency without 
some overproduction. 
163. A surplus of 58 million tons of cereals in the EEC 
is forecast for the year 2000 providing present trends 
prevail. Limitations on imports of cereal substitutes and 
maize from third countries will reduce the surplus to 38 
million tons. However. through genetic and plant hus-
bandry improvements and by introducing quotas in ani-
mal production an even larger surplus can be ex-
pected. 
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164. But there are a large number of possibilities to 
utilise cereal seed and straw in industry. The technical 
possibilities seem promising enough to absorb cereal 
surplus in industry, but the realisation of this depends 
mainly on raw material prices and on the fundamental 
problem of how to link together agriculture and indus-
try. 
165. ·Installing new types of local harvesting and 
treatment centres called · agricultural refineries' could 
increase profit per hectare considerably compared to 
the conventional technique. In principle, biotechnology 
offers the developing countries great scope for improv-
ing the food situation. However. the existing balance of 
power will prevent the developing countries profiting 
from the benefits of biotechnology to the same extent 
as the industrialised countries. It is more likely that the 
negative aspects of biotechnology will more rapidly 
become apparent to the developing countries than the 
possible positive aspects. The negative aspects include 
still greater dependence on the Western agrochemical 
industry and seed trade, fewer opportunities for export-
ing raw materials to Western countries because bio-
technology offers Western countries the possibility of 
substituting raw materials with agricultural crops. 
166. In order to achieve this goal, a new system for 
harvesting, drying and transporting the whole range of 
agricultural raw materials must be designed. The neces-
sity for a more rational utilisation of machinery in agri-
culture has today been recognised in the formation of 
machine pools. However, a further development of the 
machine-pool concept is required. The introduction of a 
whole-crop harvesting system. which in contrast to 
existing systems enables full utilisation of machinery 
throughout the whole vegetative growing season (6-8 
months), could bring down the capital costs per ton of a 
harvested product drastically. A local plant for harvest-
ing, extended with equipment for preservation and pre-
treatment of whole-plant crops, i.e. an 'agricultural refi-
nery', will not only permit collection and drying of mater-
ial for traditional use, but also add the option of indus-
trial use for components now discarded. 
167. Although contract farming can undoubtedly se-
cure significant improvement of margins when applied 
optimally, one should not fail to see that this structure 
opens up the possibility of further marginal improve-
ments when implemented as a whole-crop harvesting 
system. However, the experience so far indicates that 
the economic attraction of whole-crop harvesting is 
dependent upon the total crop utilisation; i.e. some 
degree of preparation for the industrial application of 
the crop has to take place. Provided that outlets can be 
found for the additional straw derived from whole-crop 
harvesting. trials have shown very promising results in 
respect to marginal improvements. It is suggested that 
straw should be used in increased amounts for papm 
and fibre boards to substitute for import and to make up 
for the decreasing productivity of Central European for-
ests. 
168. The suggested measures can compensate for 
any unavoidable reduction of grain prices. Community 
self-sufficiency in feed substitutes. feed protein, veget-
able oil and cellulose fibres would be increased as a 
consequence of the measures described. 
169. With the exception of marginal agricultural 
areas which are not suitable for mechanisation and 
which should be used for speciality food production, 
forestry and recreation, it seems quite feasible that by 
far the greater proportion of land now under the plough 
could be used for diversified agriculture, producing 
food, feed, fibre, building materials, industrial chemicals 
and polymers. The key to that development is to rede-
sign the interface between agriculture and industry ena-
bling us to extract economically the raw materials from 
dispersed agriculture to industry. 
170. In order to avoid a surplus of cereals in the year 
2000, it is recommended: 
(i) th,1t the EEC stimulate cooperation between agricul-
ture and industry starting by establishing agricultu-
ral refineries as demonstration units in various EEC 
countries; 
(ii) that the EEC revise its present tariff system regard-
ing cereals and cereal products and change it to a 
coherent, simplified set of rules designed to stimu-
late efficiency in cereal production and in the indus-
trial use of cereals, thus creating the basis for an 
international competitive biotechnology industry in 
the EEC; 
(iii) that the use of straw as a fibre source be stimulated 
by supporting a modernisation of the present indus-
trial process to obtain competitiveness with the 
wood-based industries; 
(iv) that the production of agricultural commodities in 
which the EEC is deficient - maize for starch. feed 
protein, vegetable oil and cellulose fibres - be sti-
mulated by quality related premium prices of present 
commodities and development of new crops; 
(v) that significant basic research programmes be esta-
blished in tile industrial manufacture of cereal based 
products including genetic engineering of plants and 
micro-organisms, the purification of cereal compon-
ents and their processing and modification into final 
products. 
Discussion 
171. In the discussion it was said that Dr. MUNCK's 
ideas would be difficult to realise. Were they not uto-
pian? 
172. Dr. MUNCK commented that a limiting factor 
will be the price of cereals. This has to go down if his 
ideas are to succeed. What the politicians can do is to 
ask themselves what the business climate here is going 
to be and decide on a certain policy, for example, a 
pricing system based on quality. By increasing produc-
tion. the price of cereals will be greatly reduced. By kilo 
the farmer will get less, but per acre he w_ill get more. 
173. Concerning overproduction Dr. MUNCK fore-
casts an annual productivity increase of ahout 5% and a 
three-lold increase in cere,11 production in tt1e year 
2000. By then we will be able to develop new possibili-
ties for using these commondities so that the surplus 
will not prevail. This is the only way forward according 
to Dr. MUNCK because if we have quotas. farming 
efficiency w:I! go down and in 20 years we will be in the 
same situation as the Eastern European countries. 
17 4. We must have reasonable food prices for urban 
dwellers. Modern biotechnology is very beneficial for 
the environment if it is applied in the right way. We can 
even correct old mistakes with it. Genetic engineering is 
making more options possible and we have to eliminate 
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the negative parts and to profit from the positive ele-
ments. 
175. Furthermore, we have to help the developing 
countries to produce their raw materials themselves. 
Their cereal production should be based on their own 
products such as millet and what we should do is to help 
them with our technology, (see, for example. the instal-
lation of agricultural refineries as described above). 
176. Some of Dr. MUNCK's ideas will not be applied 
because th~y are not in the interests of the industry. For 
example. in the Philippines a very simple and cheap 
apparatus was developed in order to economise on the 
use of fertilisers in rice fields. The fertiliser industry 
would not recommend it. 
177. Dr. MUN CK does not consider straw as a waste 
product. He mentioned that straw is already used 1n 
Danish factories but the pollution problems affects 
small companies and has to be solved, perhaps by giv-
ing financial aid to such companies. 
178. Regarding the problem of input and output of 
energy (for example, driving a car run on ethanol) Dr. 
MUNCK stressed that he wants to show in his book all 
the existing possibilities. 
179. All economic calculations and important infor-
mation concerning the new cereal circle are explained in 
the book of Dr. MUNCK and Dr. REXEN. 'Cereal Crops 
for Industrial Use in Europe'. 
5. Dr. FEILLET (JNRA, Montpellier, France): 
Biotechnology and European agricultural poli-
cy 
180. Three main points: 
- supplemt~ntary technical clarification to what was 
air eady sarcl in the Hearing, 
-- implications on tl1e level of production. 
- implications on the level of transformation. 
Remarks on the technical aspect 
181. l hf:ffe is a major difference today between bio-
technology and traditional genetics: the impact in the 
field of agriculture. 
182. Scientists do not know everything about how 
genes behave. it 1s a major technical blockage which is 
not yet sufficiently clarified. Efforts are necessary to 
develop the most traditional genetics and agronomics 
because such a knowledge is indispensable for the new 
technology 
183. The first application will appear in the animal 
production sector and afterwards in the plant produc-
tion. The food industry which was more an art than a 
science will change completely owing to biotechnoloqy 
;-11Hl beu-11 isP ot ,, ht-)tler knowl0.dqe of micro-organ-
1sms. 
184. Biotechnology is not only genetic engineering. 
Other aspects of biotechnology should be discussed 
more. Industrial progress will be seen in many other 
sciences and technologies and not only through the 
genie genetique'. 
The effect of recent progress on the production sec-
tor 
- The increasing influence of seed industries in agri-
culture: 
(i) agriculture from the farmer's side; 
seed production will be increasingly difficult to 
operate directly from the fields (hybrid seeds for 
example); 
(ii) industry supplying products to agriculture; 
for example the industry of fertilisers must be 
reorganised. 
Agriculture will become more biological,· plants will 
have more ·autonomy', for example they will be able 
to adapt better to different climates. Fertilisers and 
pesticides will be more biological. 
Positive effects: 
less fertilisers required. 
Negative effect: 
stronger resistant plants usually tend to lead to an 
increasing use of herbicides because plants are less 
likely to be affected. 
- Agricultural production better adapted to the needs 
of the consumers: 
(i) biotechnology leads to the possibility of creating 
more rapidly new species, the composition of 
which will fulfil greater industrial needs of the 
animal feed industries, 
(ii) these techniques will make possible the intro-
duction into the plants themselves of the charac-
teristics necessary for subsequent transforma-
tion (for example the industrial alterations of 
tomatoes) 
{iii) Transfer of production zones: 
Will biotechnology make possible the cultivation 
in temperate climates of tropical plants and vice-
versa? Agricultural production will develop un-
der better conditions in the Third World coun-
tries. But one should not draw conclusions too 
quickly because one must for example allow 
genes to adapt fully in their environment. 
Implications for the level of industrial transformation 
Four elements: 
- the sector of the food industry is the primary c·on-
cern; 
- the major sector of the food industry are rendered 
more independent by biotechnology;, 
-·· agricultural products become more like chemicals 
and this widens competition on the market; 
- industry, which although originating from agricul-
ture, produces no more food. 
Conclusions 
185. Tlw CAP (Common Agricultural Policy) has 
made possible the development of an intensive agricul-
ture within the area of food industry. 
186. The unique relationship between agriculture 
and the food industry disappears. As a consequence of 
this policy one should consider agricultural and indus-
trial policies together. 
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187. The multinational companies of pharmaceutical 
and petro-chemical products will control the market in 
the future. 
188. The fundamental problem of regulation will have 
to be solved. 
Discussion 
189. During the discussion Dr. FEILLET was asked 
some technical questions about ethanol on the basis of 
agricultural raw material. Dr. FEILLET recommended 
the American OTA report for information. Furthermore 
he mentioned the French Government which has devel-
oped plans for adding 6% ethanol to petrol, replacing 
the lead. In order to achieve this aim 5% of French 
wheat production would be needed. However it must be 
emphasised that biotechnology cannot in any way solve 
the surplus problem. Dr. FEILLET did not believe that 
outlets of a size capable of solving the over-production 
problem can be envisaged. On a macro-economic level 
biotechnology cannot be regarded as a solution to this 
question. No great change is foreseen in the immediate 
future. · 
190. The role of the EC States: all biotechnological 
sectors are important to the Member States; so if all 
Member States wish to have their own individual stra-
tegies. they must still be prepared to share a certain 
number of strategic areas so that resources can be 
exploited at the optimum level. It is absolutely necessa-
ry to found European expertise centres in certain sec-
tors. 
191. As to the whole crop harvesting system, men-
tioned by Or. MUNCK, Or. FEILLET thinks that the har-
vest of tomorrow will consist of proteins. glucides, 
lipides and wheat straw which will perhaps come to be 
used as a source for glucides. If it were economically 
feasible to transform cellulose into glucose there would 
be no need to grow cereals in order to extract starch. 
With today's technology this transformation is possible, 
but extremely expensive. At the moment the question of 
finding the cheapest method of producing sugar is more 
important. 
192. In the future biotechnology will tall increasingly 
under the control of multinationals as it becomes too 
expensive for smaller concerns to stand alone. 
6. Dr. VON WEIZSACKER (Institute for European 
Environmental Policy, Bonn, Federal Republic 
of Germany): 
Biotechnology and European integration and 
its impact on the environment 
193. At first glance, biotechnology does not seem to 
have much to do with European integration. Biotechno-
logy is a science and European integration is a political 
issue. Biotechnology would no doubt thrive in many 
research laboratories and industries in Europe even 
without any European integration. Nevertheless, a clos-
P.r look reveals a number of interesting connections. 
past, present and future. Some of these connections 
should be of concern to the European Parliament. 
Basic research and training 
194. Since the first FAST programme of 1978 tt1e 
Commission has emphasized the importance of bio-
technology. In many research laboratories in Europe, 
the Community initiatives in biotechnology have been 
welcomed as an important encouragement at a critical 
time. The European initiatives have triggered, or at least 
reinforced, national efforts in the same direction. In 
most European countries the lion·s share of both basic 
research and training is provided by the universities. 
rhe universities traditionally do not need any support or 
guidance from international organisations. However, as 
biotechnology is becoming · Big Science', duplication 
ought to be avoided and international collaboration has 
to be sought. Hence, the European Molecular Biology 
Laboratory in Heidelberg is regarded by many as an 
excellent example of a useful concentration of forces 
and financial means. Also, the Biomolecular Engineer-
ing Programme, launched in 1981, has already achieved 
important progress in its main goals, to remove, 
through mission-orientated research and specialised 
training actions, the bottlenecks which prevent applica-
tions in the Community of modern biochemistry and 
molecular genetics to agriculture and industry. 
Common Agricultural Policy 
195. The Common Agricultural Policy is in a phase of 
change. Productivity gains, which can be attributed to 
traditional 'biotechnology', have led to an economically 
intolerable situation. The 'Green Paper' of the EEC on 
the reform of the Common Agricultural Policy (CAP) 
places considerable emphasis on the possibility of non-
food crops and other land-use possibilities to reduce the 
pressure of food overproduction. In as much as biotech-
nology is involved in opening new alternatives, e.g. the 
production of economically viable fuel for cars, biotech-
nology has, by implication, a highly important European 
dimension. 
Environmental concerns 
196. Some writers including notably Jeremy RIFKIN 
have expressed concern about environmental and so-
cial dangers from certain new developments in biotech-
nology. notably genetic engineering. It is indeed true 
that both the construction and the release of genetical-
ly-engineered new organisms demands our close con-
cern. When Stanley COHEN and others announced in 
197 4 the successful use of the restriction enzymes for 
the insertion into bacteria of alien genetic material, a 
wave of alarm went across the globe. But. in the wake 
of the Asilomar Conference which addressed these 
problems it became increasingly clear that the manipu-
lated micro-organisms lacked the vitality to proliferate 
to any significant degree in natural environments. 
Hence, safety regulations were relaxed, and the public 
support for genetic engineering is now stronger than 
ever before. Leaving out the entire military sector, Dr. 
VON WEIZSACKER shares the views of most biotech-
nologists that the fears of a doomsday bug were greatly 
exaggerated, and that normal biotechnological routines 
under the observation of existing safety regulations do 
not pose any particular environmental problems. 
197. On the other hand, Dr. VON WEIZSACKER 
feels that a different category of dangers needs to be 
taken much more seriously. He is referring to the 'dan-
gers of success'. One automobile, one barrel filled with 
dioxine or one nuclear reactor would not be termed an 
environmental problem even if major health hazards 
were involved. Only the successful introduction of the 
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automobile in many millions of copies has created an 
environmental problem. 
198. To repeat the point with regard to agriculture: 
small scale agriculture has for thousands of years 
improved rather than damaged the environment of the 
European continent. It is only for about 35 years that 
agriculture has been ·successful'. Biotechnology will be 
perfectly acceptable from the environmental point of 
view as long as it is applied locally and in small scale. As 
said in the preceding chapter, it may even play a bene-
ficial role. However, if one imagines a functioning Com-
mon Market with comparable economic incentives to 
introduce biotechnological routines into all farms, one 
will encounter very serious environmental problems. 
Regulations 
199. One aspect of the regulation is patent law. Evi-
dently, the process of harmonisation has to be com-
pleted soon. 
200. Equally important is the harmonisation of safety 
standards, a task that was left with an ad hoe working 
group of the Science and Technology Committee of 
OECD. Contrary to earlier expectations, however, that 
ad hoe group is quite unlikely to come to a final conclu-
sion in 1985, because the United States has, in a sur-
prise move, blocked the earlier consensus. At the 
moment, it is hoped that the European Community will 
formulate the existing consensus of the OECD working 
group as a European framework for regulations. 
Discussion 
201. Concerning the 'dangers of success· Dr. VON 
WEIZSACKER stated that at the moment it is rather 
premature to speak concretely about risks to the envi-
ronment as the application area of biotechnology is only 
1 '\, of total land area. However. one must rroceed with 
caution. HP notAd that cheqtwr-t>onrd application ,s a 
morn favournble aµµroc.1ch to that of homogeneous 
application Of biotechnology. 
202. It is difficult to declare that the risks of biotech-
nologies are being ignored. There may be areas where 
knowledge is inadequate and where more research is 
necessary for risk assessment. 
203. But what we are going to regulate is different. In 
tl1e Community the essential question tO be tackled is 
that of regulating the production process and the 'suc-
cess· itself. 
204 Biotechnology can be considered as a new form 
of technology which introduces the new ethical question 
of the relationship between man and nature. This 
requires a different approach. The Commission has 
produced a new paper on agricultural policy. · The Green 
Paper'. There 1s a kind of 'industrial enthusiasm· in 
agriculture with regard to land use and alternative forms 
of agriculture We should be aware of these alterna-
tives. 
